AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05116358 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Phototherapy device
Description: The active phototherapy device will emit light
Study NCT04269070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light physical activity (LPA) condition
Description: Participants will be asked to perform 6 additional minutes per hour above their median LPA time from the observed time in the usual behavior condition.
Study NCT04269070 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual behavior condition
Description: Participants will be asked to perform their normal work activities in their normal work environment for one week. There will be no modifications to their work environment or instructions given of what activities to partake in. This period will be used to understand their normal standing and LPA behaviors to determine the personalized changes to their standing and LPA behaviors in the other conditions.
Study NCT05209399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided injection
Description: All intraarticular hip injections will be performed under real-time ultrasound guidance using a GE LOGIQ P9 ultrasound machine with a C1-5-RS 1-5 MHz curvilinear transducer (GE Healthcare, Chicago, IL, USA). For the procedure, patients will be placed in a supine position. The curvilinear transducer and ultrasound machine will be used to visualize the anterior aspect of the hip joint in a sagittal oblique plane. Sterile technique will be used to perform the procedure.
Study NCT05691907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THE therapy
Description: THE therapy consisting of:~* Heating Pad~* Interferential Therapy
Study NCT05691907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Directional Preference Exercises
Description: Directional Preference Exercises consisting of Mckenzie's extension protocol
Study NCT05691907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motor Control Exercises
Description: Motor Control Exercises consisting of External limb loading extension protocol
Study NCT05702749 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Microsurgical resection of VS
Description: Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
Study NCT05702749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microsurgical resection of VS
Description: Microsurgical resection of VSs can be accomplished by three approaches including middle cranial fossa, retrosigmoid, and translabyrinthine. The surgical approach utilized is typically selected on the basis of tumor location and size, and patient age and hearing status.
Study NCT05702749 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Stereotactic radiosurgery
Description: Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
Study NCT05702749 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiosurgery
Description: Radiation therapy will be delivered using single fraction stereotactic radiosurgery with Gamma knife technology, or linear accelerator following institutional standard of care.
Study NCT05702749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PREHAB
Description: A PREHAB visit will be done once weekly for 3 weeks to determine exercise regimen prior to surgery or radiotherapy. Therapy includes balance exercises (twice daily), gaze stabilization exercises (12-20 minutes daily), and habituation exercises (as applicable).
Study NCT05418010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tysabri Injectable Product
Description: Tysabri® is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis. Tysabri® 300mg concentrate for solution for infusion and matching placebo are collectively referred to as IMP when detailing to blinded trial procedures. Tysabri® 300mg will be colourless, clear to slightly opalescent solution.
Study NCT04898114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Nebulized magnesium sulfate (4 ml of 6.4% solution) every 15 minutes
Study NCT04898114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil Citrate
Description: Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
Study NCT04898114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Oral sildenafil citrate at an initial dose of 1 mg/kg, with incremental increases by 0.5 mg/kg every 6 hours till reaching a target dose of 2mg/kg every 6 hours.
Study NCT04898114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Nebulized isotonic saline (4 ml) every 15 minutes
Study NCT05073731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation-based Upper Extremity Training
Description: Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training.
Study NCT05418010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is colourless, clear to slightly opalescent liquid. The formulation of the is the same as that of commercial Tysabri® minus the active ingredient. Placebo is in the same containers/vials as Tysabri®.
Study NCT06340880 — intervention group
Intervention type: OTHER
Intervention: Serratus anterior plane block
Description: ultrasound guided SAPB vs anatomical landmark guided SAPB
Study NCT05073731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based Upper Extremity Training
Description: Telerehabilitation has been defined as the delivery of rehabilitation services through information and communication technologies.~Synchronized telerehabilitation provides the participant with advantages such as customized treatment, instant feedback, and a social environment such as face-to-face training.
Study NCT05783466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low-fat dairy products
Description: 3-month intervention
Study NCT05783466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-fat dairy products
Description: 3-month intervention
Study NCT05783466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk polar lipid enriched whole-fat dairy products
Description: 3-month intervention
Study NCT05019963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NexJ Connected Wellness
Description: NexJ Connected Wellness is an electronic case management platform with a patient-facing smart phone application and a clinician-facing web dashboard.
Study NCT05019963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will receive a treatment plan as decided on with their clinician(s).
Study NCT05019963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive a treatment plan as decided on with their clinician(s).
Study NCT06058351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABI-motion program
Description: The ABI-motion program strengthens the cooperation between outpatient rehabilitation professionals and community care providers.
Study NCT06033859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical measurements
Description: With the aid of a periodontal probe, the incidence of BOP, as well as PD, recession and KM will be assessed.
Study NCT06033859 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic measurement
Description: A standardized periapical radiograph of the implant will be completed at the beginning and the end of study to determine the marginal bone loss.
Study NCT06033859 — intervention group
Intervention type: PROCEDURE
Intervention: Dental prophylaxis or maintenance
Description: Dental prophylaxis or maintenance will be performed every 3 months.
Study NCT06493929 — intervention group
Intervention type: OTHER
Intervention: Chest ultrasound
Description: to assess diaphragmatic excursion (DE(. M-mode was used to record the movement of the diaphragm during tidal breathing when the sampling line and diaphragm were as vertical as possible (not \< 70°). The data was measured from the first respiratory cycle at 0 min after SBT.
Study NCT06493929 — intervention group
Intervention type: OTHER
Intervention: Calculation of Mechanical Power on the first day of intubation and before First trial of weaning:
Description: Total respiratory rate (RR). Positive end-expiratory pressure (PEEP) (the external or applied PEEP) recorded, not the total PEEP, or intrinsic PEEP. The plateau pressure (Pplat) was measured during an inspiratory pause on the ventilator. Peak inspiratory pressure (Ppeak) should be obtained while the patient is relaxed, not coughing or moving in bed. MP was calculated according to Gattinoni's simplified mechanical power equation as follows (3,8):~MP(J/min)=0.098×VT×RR×(Ppeak-0.5×ΔP).
Study NCT06583837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib was administrated for 12 weeks
Study NCT06583837 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: response-adapted radiation
Description: response-adapted ultra-low dose 4Gy radiation
Study NCT04939428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four molnupiravir 200 mg capsules taken by mouth.
Study NCT04939428 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
Study NCT04517851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV
Study NCT04517851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05930756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Genicular radiofrequency ablation uses thermal energy to percutaneously create lesions in neural tissues of the genicular nerves that innervate the anterior knee capsule and disrupt the conduction of pain signals.
Study NCT06638593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIRRORS-FROZEN Protocol.
Description: Initial laparoscopic phase and thorough inspection of the abdomino-pelvic cavity to determine the feasibility of proceeding robotically, followed by robotic excision of the mass(es) and its retrieval in a bag if deemed suitable to proceed robotically. The mass or cyst will be sent for frozen section to determine the extent of the surgery. The surgery will continue robotically, with conversion to laparotomy considered at any point at the discretion of the individual surgeon.
Study NCT06638593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard open surgery
Description: A midline abdominal incision will be made from the outset, with intraoperative frozen section assessment to determine the extent of the surgery.
Study NCT04709393 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FRAX+SARC-F questionnaire pre-screening
Description: Pre-screening group participants will receive the FRAX+SARC-F questionnaire pre-screening and be notified of the preliminary estimation of their future hip fracture risk before being invited to our DXA screening and fall-risk assessment.
Study NCT06636825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded hypercapnia
Description: Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
Study NCT06636825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Graded hypercapnia
Description: Volunteers breathe 0%, 2%, 4%, 6%, and 8% CO2 (with 21% O2, balance nitrogen) for 12 minutes each
Study NCT06636825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 400 mg caffeine capsule taken in a single dose 1 hour prior to graded hypercapnia
Study NCT06636825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (microcrystalline cellulose) capsule taken in a single dose 1 hour prior to graded hypercapnia
Study NCT06637735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: pregnant women will be given a 4-week training and the pre-test post-test will be analyzed
Study NCT06049160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: All participants will be assigned for giving misoprostol rectally either preoperative or postoperative
Study NCT05960435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: PNF, a method used to increase the range of motion of the joint and strengthen the muscles in the newly gained range, is a holistic approach and is based on motor learning principles. PNF stretching involves isometric contraction of the target muscle in addition to static stretching.
Study NCT05960435 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group Exercise
Description: The control group will include static stretching, capsule stretching, progressive ROM exercises and strengthening exercises.
Study NCT04833075 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood sampling
Description: A maximum of 13 blood samples (39 mL) will be derived from subjects on treatment. After discontinuation of ICI treatment, a maximum of 7 blood samples (21 mL) will be derived.
Study NCT06512818 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psiguavin
Description: A purified guava extract will be used, enriched in psiguavin
Study NCT06512818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with the same characteristics that Psiguavin intervention but filled with a placebo compound
Study NCT06204666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Hemp Fiber Bar
Description: High dose hemp fiber bar with other ingredients
Study NCT04669678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel (ETG) implant
Description: Contraceptive progestin implants are thin rods inserted under the skin of a woman's arm. The most widely available implant in South Africa is currently Implanon®/Nexplanon®/Implanon NXT®, containing etonogestrel (ETG, 3-keto desogestrel). Implanon® consists of a single rod of ethylene vinyl acetate and contains 68 mg of ETG; it is manufactured by Merck and is approved for 3 years.
Study NCT04669678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
Study NCT04669678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular depo-medroxyprogesterone acetate (IM DMPA)
Description: DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide, and the most commonly used method of reversible injectable contraception in sub-Saharan Africa.
Study NCT04669678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub-cutaneous medroxyprogesterone acetate (SC MPA)
Description: SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection. Sayana® Press is indicated for medium-long term female contraception.
Study NCT05041699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IPM Ring-105
Description: DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
Study NCT05041699 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: IPM Ring-106
Description: DPV-LNG Ring containing xx mg of dapivirine + xx mg of levonorgestrel
Study NCT06138158 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise and Education Group
Description: Physical exercise and pain education
Study NCT05516147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAFE at Home
Description: SAFE at Home will enable community-dwelling PWD to participate in videoconference-based group activities with their peers, that is, other PWD. SaH sessions will be facilitated by highly trained Engagement Professionals.
Study NCT04508530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panzyga
Description: Panzyga 10% IVIG
Study NCT04669678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hormonal intrauterine device (IUD)
Description: The NOVA T-380 non-hormonal IUD consists of a T-shaped polyethylene frame wound with copper wire, along with two monofilament threads to aid in removal of the IUD. IUDs may be left in place for up to 5 years.
Study NCT04508530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06199882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBRT Sequential Surufatinib Combined With Immunotherapy
Description: 1. SBRT :~   Bioequivalent total dose > 75Gy, completed within 2 weeks (once daily, 5 times a week).~2. Drug treatment (every 3 weeks is a treatment cycle) :~1) Surufatinib: 200 mg, po, qd, taken continuously; 2) Carrelizumab: 200 mg/ time, intravenous drip on the first day of each cycle.
Study NCT06637475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric stimulation
Description: Patients with baseline assessments will be followed up for 8 weeks within a planned treatment program. Treatment protocol for the ES group:~external ES wearable apparatus will be applied three days a week for 30 minutes with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 s contraction and 5 s rest, with a current intensity ranging from 0-100 mA while the patients are in the supine position. The device will be attached to the patients in such a way that it wraps around the upper thigh, the electrodes will be attached to the anterior and posterior of the right and left thigh, the right-left pelvic side and the right-left gluteal region. The current intensity in each session will be determined as the maximum current intensity that will not cause pain and discomfort in individuals.
Study NCT06640452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoveryFun system
Description: The system components were: VR headset; wereable biosensors, clinical platform, caregiver app and smart services.
Study NCT06637852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUFICS-PACT
Description: SUFICS-PACT includes sexual and urinary dysfunction screening, collaborative treatment of sexual and urinary dysfunction, and care managers who are mental health professionals with training in psychosexual counseling. Mental health professionals will facilitate a comprehensive approach to sexual dysfunction, as emphasized by the biopsychosocial model of sexual health. SUFICS-PACT also emphasizes close follow up, which is important for sexual function recovery after prostate cancer treatment.
Study NCT06636812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium
Description: Single dose losartan (25mg or 50 mg, weight-adjusted), encapsulated identically to placebo
Study NCT06636812 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single tablet encapsulated identically to placebo
Study NCT06638086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen Suppositories
Description: Per rectal suppositories
Study NCT06638086 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Injection
Description: Intra-venous injection
Study NCT06641024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MC-1-50
Description: A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy
Study NCT06639113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administration medicines
Description: Management of drugs' administration by the patient
Study NCT05359328 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Pulse Oximeter, Respiratory Rate, Heart Rate and Arterial line
Description: Measurement of physiological parameters
Study NCT05746273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Participants will wear nicotine transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Active dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study NCT05746273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Placebo Patch
Description: Participants will wear placebo transdermal patches daily for 12-15 weeks. They will apply a study patch each morning and remove at bedtime. Placebo patch dose will titrate up from 3.5mg to 7mg, and then can optionally be further titrated to a maximum dose of 14mg. After week12, the dose will be slowly tapered over 2-3 weeks.
Study NCT04620668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wysa
Description: Wysa is an AI-based mental health chatbot. It uses evidence-based techniques to help users build mental resilience skills and improve their mental health.